A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
暂无分享,去创建一个
Catherine J. Wu | J. Ritz | S. Nikiforow | P. Armand | M. Davids | R. Soiffer | Yi-Bin Chen | P. Bachireddy | F. Locke | E. Ball | C. Cutler | D. Avigan | A. Bashey | Haesook T. Kim | C. Costello | V. Ho | E. Alyea | A. Herrera | H. Streicher | R. Maegawa | Alexandra Savell | Michael Mazzeo | A. Anderson | Alexander P. Boardman | Augustine Weber | A. Savell
[1] J. McCarty,et al. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy , 2019, Leukemia & lymphoma.
[2] M. Brock,et al. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Tonon,et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation , 2019, Nature Medicine.
[4] C. Craddock,et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Claus,et al. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. , 2018, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.
[6] L. Obéric,et al. Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers , 2018, American journal of hematology.
[7] M. Davids,et al. Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. , 2018, Blood.
[8] P. Hari,et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. , 2017, Blood.
[9] R. Houot,et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. , 2017, Blood.
[10] R. Advani,et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. , 2016, Blood.
[11] Catherine J. Wu,et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[12] J. Aster,et al. Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. , 2016, The Journal of molecular diagnostics : JMD.
[13] G. Freeman,et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. , 2016, The Journal of clinical investigation.
[14] J. Ritz,et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. , 2016, Blood.
[15] P. Bousso,et al. The PD-1 Axis Enforces an Anatomical Segregation of CTL Activity that Creates Tumor Niches after Allogeneic Hematopoietic Stem Cell Transplantation. , 2016, Immunity.
[16] S. Devine,et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] P. Armand,et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] G. Freeman,et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. , 2013, Blood.
[19] A. Korman,et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. , 2011, Cancer research.
[20] E John Wherry,et al. T cell exhaustion , 2011 .
[21] C. Klein,et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. , 2011, Blood.
[22] W. Shannon,et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.
[23] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] I. Lowy,et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. , 2009, Blood.
[25] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[26] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Barlogie,et al. International uniform response criteria for multiple myeloma , 2006, Leukemia.
[28] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[29] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Panoskaltsis-Mortari,et al. Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1 , 2003, The Journal of Immunology.
[31] A. Sharpe,et al. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. , 1999, Journal of immunology.